IN8bio Earnings Call Transcripts
Fiscal Year 2026
-
The company is advancing a pan-gamma-delta T cell engager for autoimmune and oncology indications and a drug-resistant immunotherapy for glioblastoma, both showing promising efficacy and safety. Repeat dosing and deep immune profiling differentiate their approach, with strong financials supporting progress toward pivotal trials and regulatory engagement in 2024.
-
Gamma delta T cell therapies showed promising clinical results in glioblastoma and leukemia, with no major toxicities and statistically significant survival benefits. The proprietary T-cell engager platform targets autoimmune diseases with reduced toxicity, and key clinical and preclinical milestones are expected later this year.
-
Gamma delta T cell therapies show long-term remissions in AML and glioblastoma, with repeat dosing linked to improved survival. A new T cell engager platform demonstrates potent B cell depletion and reduced cytokine release, with key animal data and regulatory milestones expected later this year.
-
The company presented strong clinical data for its gamma-delta T cell therapies, showing significant survival benefits in glioblastoma and progress in leukemia and T cell engager programs. Recent financing secures operations through 2027, with key data and regulatory milestones expected this year.
Fiscal Year 2025
-
New data unveiled for a gamma-delta T cell engager platform targeting both cancer and autoimmune diseases, with clinical trials showing durable remissions and reduced toxicities. The approach offers potent B cell depletion without lymphodepletion, aiming for safer, more accessible therapies.
-
Gamma delta T-cell therapies show promising long-term remissions in AML and glioblastoma, with no relapses in AML patients and survival rates surpassing benchmarks. New data on T-cell engagers and solid tumor programs are expected later this year.
-
A phase I trial of allogeneic gamma-delta T cells (INB-100) in high-risk AML patients post-transplant showed no relapses and 100% survival at one year, with a strong safety profile and significant improvement over historical controls. Expansion to more patients and centers is ongoing.
-
Gamma delta T cell therapies show strong safety and efficacy, with durable remissions in leukemia and promising results in glioblastoma. Multiple clinical and preclinical data updates are expected this year, supported by a robust team and sufficient funding.
Fiscal Year 2024
-
A strategic shift prioritizes INB-100 for leukemia, with early data showing durable remissions and strong safety. INB-200 and other assets are paused or seeking partnerships amid a tough funding climate, and workforce reductions aim to extend cash runway.
-
Multiple clinical programs are advancing, with INB-200 and INB-100 showing durable remissions in GBM and leukemia, respectively. Gamma delta T cell therapies demonstrate unique persistence and safety, with upcoming data and trial updates expected later this year.